# An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)

> **NCT01759264** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 101 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01759264
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01759264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01759264, "An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01759264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*